TV18’s Timsy Jaipuria, Krishna M Ella, Executive Chairman of Bharat Biotech, discusses the growing threat of antimicrobial ...

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Bharat Biotech partners with GSK to lead Phase 3 trials and manufacturing of altSonflex1-2-3, targeting deadly Shigella ...

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.